Cart
Orders
Not available here
Product Overview
CELOSOME Soft, Mid, Strong and Implant are four cross-linked hyaluronic acid (HA) dermal fillers from the Korean CELOSOME product range. Each formulation contains 24 mg/mL HA and 0.3% lidocaine and is supplied in a 1.1 mL prefilled syringe. The four products differ primarily in their relative gel viscoelasticity, offering distinct formulation profiles within the same filler family. From the softer CELOSOME Soft to the firmer CELOSOME Implant, the range is positioned for different facial correction and volume-support applications. This product page allows professional buyers to compare the four formulations, their shared specifications and distinguishing characteristics before selecting a product option.
Key Features
- Four Distinct Gel Profiles CELOSOME Soft, Mid, Strong and Implant are differentiated by relative gel viscoelasticity, progressing from softer formulations to firmer gels designed for different aesthetic correction profiles.
- 24 mg/mL Cross-Linked Hyaluronic Acid All four formulations contain the same stated HA concentration. Their distinguishing characteristics are associated with the properties of the finished gel rather than differences in HA concentration alone.
- 0.3% Lidocaine Formulation The documented CELOSOME Soft, Mid, Strong and Implant presentations contain 3 mg/mL lidocaine, a local anesthetic component included in the filler formulation.
- HENM Cross-Linking Technology CELOSOME product literature describes HENM as the cross-linking technology associated with the range. Different gel characteristics are achieved through the manufacturer's formulation approach.
- Standardized 1.1 mL Presentation Each listed formulation is supplied as one 1.1 mL prefilled syringe per box, allowing professional buyers to compare the four products using a consistent presentation format.
Composition & Specifications
| Specification | Details |
|---|---|
| Product Family | CELOSOME Soft / Mid / Strong / Implant |
| Product Category | Cross-linked hyaluronic acid dermal filler |
| Primary Material | Stabilized, cross-linked hyaluronic acid (HA) |
| HA Concentration | 24 mg/mL |
| Lidocaine Content | 0.3% (3 mg/mL) |
| Formulation Technology | HENM cross-linking technology, as described in CELOSOME product literature |
| Gel Characteristics | Variant-specific relative viscoelasticity |
| Syringe Volume | 1.1 mL |
| Packaging | 1 prefilled syringe per box, according to referenced sales documentation |
| Country of Origin | Republic of Korea, distributor-reported |
| Official Sales Partner | JDBIO Co., Ltd. |
| Legal Manufacturer | To be confirmed against the original manufacturer-issued product label |
Specifications refer to the CELOSOME Soft, Mid, Strong and Implant formulations described in published sales documentation. Product packaging, regulatory classification and authorized indications may vary by market. Confirm the exact supplied SKU and current Instructions for Use before professional use.
How CELOSOME HA Fillers Work
Hyaluronic acid is a naturally occurring component of the extracellular matrix and has a strong capacity to associate with water. In cross-linked dermal fillers, HA chains form a cohesive gel that can provide temporary physical volume and support within soft tissue. Cross-linking influences the mechanical properties of the finished formulation, including its resistance to deformation and its behavior under applied forces.
Although CELOSOME Soft, Mid, Strong and Implant share the same listed HA concentration, their relative viscoelasticity differs. CELOSOME Soft is positioned as the most adaptable formulation, while Mid and Strong represent progressively firmer gel profiles. CELOSOME Implant is described as the firmest formulation in this four-product range. These characteristics describe the product family's relative gel properties. They do not independently establish clinical superiority, treatment duration or authorization for a particular anatomical application.
Compare CELOSOME Soft, Mid, Strong & Implant
The four CELOSOME fillers share the same HA concentration, lidocaine content and syringe volume. The primary difference is their relative gel profile, which supports different product positioning within the CELOSOME dermal filler range. The following comparison is intended to help professional buyers identify the distinguishing characteristics of each formulation.
| Product | Relative Gel Profile | Brand-Described Positioning | HA | Lidocaine | Presentation |
|---|---|---|---|---|---|
| CELOSOME Soft | Soft / Low Viscoelasticity | Fine facial lines and subtle volume correction | 24 mg/mL | 0.3% | 1.1 mL × 1 syringe |
| CELOSOME Mid | Medium Viscoelasticity | Moderate facial folds and soft-tissue volume correction | 24 mg/mL | 0.3% | 1.1 mL × 1 syringe |
| CELOSOME Strong | Firm / High Viscoelasticity | Deeper facial folds and contour-support applications | 24 mg/mL | 0.3% | 1.1 mL × 1 syringe |
| CELOSOME Implant | Firmest / Highest Relative Viscoelasticity | Facial volume enhancement and contour-support applications | 24 mg/mL | 0.3% | 1.1 mL × 1 syringe |
The relative gel profiles and applications summarize published CELOSOME product positioning. They do not represent numerical rheological measurements or universally approved clinical indications. Review market-specific product labeling before professional use.
Professional Product Selection Considerations
When comparing CELOSOME Soft, Mid, Strong and Implant, professional buyers should distinguish the products by their formulation characteristics rather than HA concentration alone. All four presentations share 24 mg/mL HA, 0.3% lidocaine and a 1.1 mL prefilled syringe format, making their relative gel properties the main differentiating factor within this range.
- Verify the Exact Formulation Confirm whether the selected product is Soft, Mid, Strong or Implant. Each name identifies a different gel profile within the same CELOSOME filler family.
- Check HA and Lidocaine Specifications The listed formulations contain 24 mg/mL HA and 0.3% lidocaine. Verify these details against the actual product label, particularly when purchasing for different destination markets.
- Confirm Packaging The referenced presentation contains one 1.1 mL prefilled syringe per box. Package configuration and any supplied accessories should be checked against the original product packaging.
- Review Market-Specific Authorization Product registration, legally authorized indications and professional-use requirements may differ by country. The marketed correction profiles should not be interpreted as universal regulatory approvals.
Storage & Handling
Published CELOSOME distributor information describes storage at 2–25°C, protected from direct sunlight and freezing. The latest manufacturer-issued Instructions for Use for the exact product presentations were not independently verified. Storage conditions printed on the original product carton and the applicable market-specific labeling should take precedence.
CELOSOME Soft, Mid, Strong and Implant are professional-use injectable dermal fillers. Product identity, expiration date, packaging integrity and relevant safety information should be checked before use. Injectable HA fillers can cause adverse events, including infection, nodules and serious vascular complications. Administration is restricted to appropriately qualified healthcare professionals in accordance with applicable regulations.
Frequently Asked Questions
What is the difference between CELOSOME Soft, Mid, Strong and Implant?
The four products primarily differ in their relative gel viscoelasticity. Soft has the lowest relative firmness, followed by Mid and Strong, while Implant is positioned as the firmest formulation in the range. All four share 24 mg/mL HA, 0.3% lidocaine and a 1.1 mL syringe volume.
Do all four CELOSOME fillers contain the same amount of hyaluronic acid?
Yes. The CELOSOME Soft, Mid, Strong and Implant formulations covered here are each listed at 24 mg/mL cross-linked HA. Their gel properties differ despite the shared concentration.
Do CELOSOME Soft, Mid, Strong and Implant contain lidocaine?
The documented presentations contain lidocaine at 0.3%, equivalent to 3 mg/mL. Confirm the exact formulation on the supplied product label before professional use.
How many syringes are included in a CELOSOME filler box?
The referenced CELOSOME Soft, Mid, Strong and Implant presentations each contain one 1.1 mL prefilled syringe per box. Verify the actual package configuration for the selected product and destination market.
What is HENM technology?
HENM is the cross-linking technology described in CELOSOME brand literature. It is associated with the formulation of HA gels with different viscoelastic characteristics. Its use does not, by itself, establish clinical superiority or guaranteed treatment duration.
Is CELOSOME Implant the same as CELOSOME Strong?
No. Although both contain 24 mg/mL HA and 0.3% lidocaine, CELOSOME Implant is positioned as the firmer formulation for volume and contour-support applications. CELOSOME Strong is described as a comparatively less firm formulation within the same range.